{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-044747","form_type":"8-K","ticker":null,"cik":"0001708331","company_name":"Virpax Pharmaceuticals, Inc.","filed_at":"2024-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.684073+00:00","generated_at":"2026-06-01T16:13:40.410953+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Virpax prices $2.25M public offering of common stock and warrants","bullets":["Gross proceeds of ~$2.25M from offering of 1,666,667 shares/equivalents plus Series A-1 and A-2 warrants.","Series A-1 warrants exercisable at $1.35/share, expire in 5 years; Series A-2 at $1.35/share, expire in 18 months.","Proceeds to be used for working capital, general corporate purposes, and possibly settling a portion of an obligation.","After closing, 2,741,600 shares of common stock outstanding.","A.G.P./Alliance Global Partners acted as sole placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-044747","json":"https://secwatch.observer/filing/0001213900-24-044747.json","markdown":"https://secwatch.observer/filing/0001213900-24-044747.md","text":"https://secwatch.observer/filing/0001213900-24-044747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708331/000121390024044747/0001213900-24-044747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708331/000121390024044747/ea0206438-8k_virpax.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T16:13:40.410953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6af056659c17797a1b737c2e4bc48bca70e9100e","claim":"Virpax Pharmaceuticals, Inc. entered into Purchase Agreement with certain investors (effective 2024-05-14).","evidence_excerpt":"In connection with the Offering, on May 14, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000121390024044747/0001213900-24-044747-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Effective","value":"2024-05-14"}],"fact_type":"material_agreement"},{"claim_id":"c3b684d96ddd48ff3b471b78d2df894f45283486","claim":"Virpax Pharmaceuticals, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (effective 2024-05-14).","evidence_excerpt":"Also, in connection with the Offering, on May 14, 2024, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000121390024044747/0001213900-24-044747-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Effective","value":"2024-05-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}